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Introduction
Tobramycin is an aminoglycoside antimicrobial drug and 
is the cornerstone in anti-Pseudomonas aeruginosa (Psa) 
therapy in Cystic Fibrosis (CF) and non-CF bronchiec-
tasis patients [1,2]. Furthermore, it is frequently used 
to treat severe infections caused by tobramycin sensi-
tive micro-organisms in hospitalised patients [3]. With 
the introduction of  the TOBI® Podhaler™ (dry pow-
der inhaler with tobramycin), pulmonary administraion 
of  tobramycin is likely to become even more popular 
in the treatment of  CF and non-CF bronchiectasis pa-
tients colonised with Psa, since dry powder inhalation is 
much more user-friendly [4]. Tobramycin therapy is op-
timised by drug monitoring but the compound lacks a 
chromophore group and it is, therefore, very challeng-
ing to determine its concentration in serum or plasma 
by standard high-performance liquid chromatography 
(HPLC) with UV detection. A frequently used method 
to quantify tobramycin in serum or plasma is with an 
immunoassay method. However, a disadvantage of  im-
munoassays for tobramycin is the limit of  detection of  
0.2 mg/L. Immunoassay methods are suitable to mea-
sure trough and peak concentrations of  intravenously 
administered tobramycin, but they lack the sensitivity to 
evaluate lower concentrations of  tobramycin for phar-
macokinetic studies of, for instance, inhaled (dry powder) 
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RESEARCH ARTICLE
Tobramycin is an aminoglycoside antimicrobial drug frequently used in anti-pseudomonal thera-
py in cystic fibrosis and non-cystic fibrosis bronchiectasis patients. Therapeutic drug monitoring 
is routinely performed to increase efficacy and reduce the chance of  toxicity. The most frequently 
used method to quantify tobramycin in serum or plasma is with an immunoassay method. How-
ever, immunoassays lack sensitivity to evaluate the lower concentrations of  tobramycin for phar-
macokinetic studies of  for instance inhaled tobramycin. The aim of  this study was to optimise 
the Syva® Emit® 2000 Tobramycin Assay combined with the ARCHITECT c8000. This adapted 
method was validated for accuracy and precision, having within-run, between-run variation. The 
adapted tobramycin immunoassay method has a linear range of  0.03 to 0.6 mg/L, which is com-
parable to liquid chromatography-mass spectrometry methods. The immunoassay method was 
validated with representative samples and has been implemented in routine analysis.
Keywords: ARCHITECT, tobramycin, immunoassay, EMIT.
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tobramycin. Therefore, analytical methods using liquid 
chromatography-mass spectrometry (LC-MS) and other 
more complex LC methods have been developed. These 
methods often need derivatisation of  the samples before 
tobramycin can be detected [5–9], this is time-consuming 
and expensive. Furthermore, the analytical robustness of  
these methods at lower limit of  quantification (LLOQ) 
is limited. A more promising approach could be adapta-
tion of  existing immunoassay methods. Immunoassays 
are widely used, relatively cheap and easy to perform [10]. 
Previously, the sensitivity of  a tobramycin immunoassay 
has successfully been increased [11]. However, the TDx-
FLx platform used for this method has been discontin-
ued. Therefore, the aim of  this study was to optimise 
the Syva® Emit® 2000 Tobramycin Assay combined with 
the ARCHITECT c8000, to be able to quantify concen-
trations 10 times lower than 0.2 mg/L suitable for use 




The Syva® Emit® 2000 Tobramycin Assay and Syva® 
Emit® 2000 Calibrators were purchased from Siemens 
(Siemens Nederland NV–Health sector, Den Haag, 
the Netherlands). All chemicals used were of  analytical 
grade. Human serum was made available according to 
standard hospital procedures. Only plastic pipette tips, 
sample tubes and analyser reagent containers were used 
to prevent tobramycin adsorption to glass surfaces [12].
Methods
Enzyme multiplied immunoassay technique
The analyser used during this research is the ARCHI-
TECT c8000 (Abbott Diagnostics, Chicago, USA). The 
Syva® Emit® 2000 Tobramycin Assay is a homogenous 
enzyme immunoassay technique. The tobramycin con-
centration in a sample can be measured in terms of  en-
zyme activity. Active enzyme  converts oxidised NAD to 
NADH, resulting in an absorbance change that is mea-
sured spectrophotometrically. The Syva® Emit® 2000 To-
bramycin Assay and Syva® Emit® 2000 Calibrators were 
used as described in the package insert. The assay was 
calibrated using three calibration points in the lowest 
concentration range and all routine measurements were 
performed as single measurements.
Optimisation of  the limit of  quantification
The higher limit of  quantification (HLOQ) and LLOQ 
are affected by the coefficient of  variation (CV) of  the 
immunoassay. The HLOQ can easily be circumvented 
by dilution of  the samples. However, the LLOQ is pri-
marily determined by the sensitivity of  the method and, 
therefore, harder to reduce. To lower the LLOQ the main 
parameter to be optimised was the sample volume. The 
sample volume was increased from the standard 3 µL to 
18 µL to increase the total amount of  tobramycin to be 
measured in the sample and thus, the sensitivity of  the 
method. Accordingly the HLOQ is expected to be low-
er. By varying the sample volume, the measuring range 
of  the Syva® Emit® 2000 Tobramycin Assay, in which it 
can accurately quantitate tobramycin concentrations, can 
be significantly increased. To demonstrate that increasing 
the sample volume does not have a profound effect on 
the sensitivity of  the assay, the method was extensively 
validated.
Method validation
This method was validated for accuracy and precision 
[13,14]. For the accuracy the bias should not exceed 15%, 
or should not exceed 20% for LLOQ determination. For 
the precision the CV should not exceed 15%, except for 
the LLOQ, for which the CV should not exceed 20%. 
Precision was assessed by evaluation of  within-run and 
between-run CVs. For determination of  the LLOQ and 
for QC the following concentrations of  tobramycin in 
human serum were prepared: 0.03, 0.05, 0.10, 0.15 and 
0.20 mg/L. For determination of  the range for this 
method the additional following concentrations of  to-
bramycin in human serum were prepared: 0.45 and 0.6 
mg/L. As a measure for the increased sensitivity, the ac-
curacy and the precision of  the assay, the bias and with-
in-run, between-run and overall CV were determined. All 
levels (LLOQ and QCs) were measured 5 times a day 
for 3 consecutive days. The total replicate number (n) for 
each level is therefore 15. Calibration was done by using 
two commercial calibrators at the lowest level (0.0 mg/L 
and 0.6 mg/L). A third intermediate calibration-level was 
created by the Architect-analyser by means of  a dilution. 
Cross-reactivity
Despite the sensitivity of  immunoassay methods, 
cross-reactivity with endogenous and exogenous com-
pounds (e.g. drugs) may occur. Therefore, the cross-re-
activity of  this method with different drugs in human 
serum was investigated. These drugs were: azithromycin, 
ursodeoxycholic acid, esomeprazole, prednisolone, flu-
cloxacillin, sulfamethoxazole, n-acetyl sulfamethoxazole, 
trimethoprim, ciprofloxacin, mycophenolic acid, tacro-
limus, ceftazidime, colistin, gentamicin, kanamycin and 
amikacin. The latter three are aminoglycoside antibiot-
ics like tobramycin, and are therefore expected to show 
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some cross-reactivity (positive controls), since they have 
similar structural formulas. The other compounds are 
drugs that are often used in the treatment of  CF patients 
and could be co-administrated with tobramycin.
Results
Lower limit of  quantification
The bias and the CVs were determined with tobramycin 
concentrations between 0.03 and 0.6 mg/L as a measure 
for the increased sensitivity of  the method. After mea-
suring the LLQQ (0.03 mg/L) and the QCs (0.03 – 0.05 
– 0.10 – 015 and 0.20 mg/L) in a frequency of  5 times a 
day for 3 days (n=15) the bias and CVs were calculated. 
Table 1 shows that the bias is within the defined limits of  
15% [13] and that the  bias and CVs for the QCs are with-
in the defined specification of  20% [14]. The within-run 
CV varied from 1.9% – 12.2% and between-run from 
0% – 6.6% and, therefore, the requirements for accuracy 
and precision (Table 2) were met. 
Calibration curve
To investigate and demonstrate the applicability of  the 
analytical procedure, the range of  the calibration curve 
between 0 and 0.6 mg/L was investigated with in-house 
prepared QC samples (Figure 1). The theoretical (calcu-
lated) value was plotted against the measured value and 
Figure 1 shows that the measured values correlate with 
the prepared concentrations. 
 
Cross-reactivity
A range of  compounds was investigated for drug inter-
ference (Table 3). As expected, kanamycin and amika-
Table 1. Determination of  accuracy and overall precision














The bias (%) was calculated by:  (Average concentration-Nom-
inal concentration)/(Nominal concentration)*100% and the 
coefficient of  variation (%) by: (Standard deviation)/(Av-
erage concentration)*100%. All tobramycin concentrations 
were measured 5 times on 3 consecutive days (n=15 per con-
centration).













N-Acetyl sulfamethoxazole 94.2 <0.03
Trimethoprim 7.58 <0.03
Ciprofloxacin 18.78 <0.03







Most compounds investigated - most at extremely high con-
centrations compared to their therapeutic range - did not 
show cross-reactivity. The latter three are aminoglycoside 
antibiotics like tobramycin, and are therefore expected to 
show some cross-reactivity (positive controls), since they 
have similar structural formulas. The other compounds are 
drugs that are often used in the treatment of  CF patients and 
could be co-administrated with tobramycin.
Table 2. Determination of  within-run and between-ru
precision of  the method.
Tobramycin concentration
(mg/L)










The coefficients of  variation (%) were calculated by: (Stan-
dard deviation)/(Average concentration)*100%. All tobra-
mycin concentrations were measured 5 times on 3 consecu-
tive days (n=15 per concentration).
and easier to perform than HPLC based analytical pro-
cedures, which suffer from the need for sample derivati-
sation before tobramycin can be analysed with fluores-
cence, electrochemical or UV detectors. LC-MS methods 
have also been developed, but these are time-consuming 
and expensive too. Furthermore, the analytical robust-
ness of  these methods at lower LLOQ is limited, while 
equipment to perform immunoassays (like the ARCHI-
TECT c8000) are more widespread and easier to operate. 
Moreover, the currently used analysers (like the ARCHI-
TECT c8000) offer more freedom with regard to varying 
the settings than older systems, this opens the way to new 
applications like the method described in this paper. 
This study presents a validated, simple and rapid analyti-
cal method using an immunoassay for the quantification 
of  tobramycin in human serum at a concentration level 
approximately 10 times lower compared to the standard 
procedure. This method was validated for accuracy and 
precision [12,13], having within-run, between-run and 
overall CVs lower than 20% for the LLOQ and lower 
than 15% for other QC levels (Tables 1 and 2). The 
method has a range of  0.03 to 0.6 mg/L, which was com-
parable to LC-MS/MS methods used in earlier studies 
[5,6]. 
Since kanamycin and amikacin cross-react with the to-
bramycin assay, this assay cannot be used to accurately 
quantitate tobramycin serum (or plasma) levels in pa-
tients receiving any of  these drugs in combination with 
tobramycin. Considering the different indications of  
these drugs co-administration is unlikely and could be 
checked for by the Lab. The package insert from Siemens 
states that only very high concentrations of  gentamicin 
(100 mg/L) could affect the results. Despite the increased 
sensitivity of  the procedure, analysing a sample with 10 
mg/L of  gentamicin (within the therapeutic range) did 
not show any interference with the adapted assay. All 
other compounds investigated - most at extremely high 
concentrations compared to their therapeutic range - did 
not show cross-reactivity either (Table 3). If  these com-
pounds do not interfere with the assay at very high con-
centrations, cross-reactivity of  these compounds in lower 
concentrations is also ruled out.
The newly validated immunoassay method enables the 
quantification of  low concentrations of  tobramycin in 
serum. The adapted method with increased sample vol-
ume is much more sensitive than the specifications of  
the Syva® Emit® 2000 Tobramycin Assay with standard 
sample volume, and the sensitivity is comparable to more 
time-consuming LC-MS/MS methods presented in the 
literature. 
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Figure 1. Calibration curve of  the adapted immunoassay 
method for tobramycin. The dark grey line indicates the linear 
fit and the dashed lines indicate the 95% confidence intervals. 
The open circles indicate the measured values.
cin showed cross-reactivity with the Syva® Emit® 2000 
Tobramycin Assay. Tobramycin, kanamycin and amika-
cin have very similar structural formulas and this causes 
cross-reactivity [15]. 
Gentamicin – also an aminoglycoside antibiotic – did not 
show any cross-reactivity. A possible explanation for this 
is that the other three are more structurally related since 
they are produced by bacteria from the Streptomyces ge-
nus, while gentamicin is produced by bacteria from the 
Micromonospora genus. With all other compounds in-
vestigated no cross-reactivity was observed. 
Discussion
According to the specifications of  the Syva® Emit® 2000 
Tobramycin Assay it can accurately quantitate tobramy-
cin concentrations in human serum or plasma containing 
0.2-10 mg/L tobramycin (without dilution). By increas-
ing the sample volume we were able to increase the sen-
sitivity of  this immunoassay. This validated method has 
already been used for serum-concentration analysis of  
tobramycin in a pilot study with 8 non-CF bronchiectasis 
patients (manuscript under review). 
In this study the participants received tobramycin, as the 
free base, administered with a new disposable dry pow-
der inhaler called the Cyclops [16]. After pulmonary ad-
ministration of  relatively low tobramycin doses, the se-
rum-concentrations are too low for quantification with 
standard tobramycin immunoassay methods. We chose 
this approach, because immunoassays are generally faster 
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a Fluorescence Polarographic Immunoassay with 
Increased Sensitivity for Measurement of  Low Con-
centrations of  Tobramycin in Serum. Ther. Drug 
Monit. 18, 189–193 (1996).
12, Josephson L, Houle P, Haggerty M. Stability of  di-
lute solutions of  gentamicin and tobramycin. Clin. 
Chem. 25, 298–300 (1979).
13. European Medicines Agency & Committee for 
Medicinal Products for Human Use (CHMP). 




14. U.S. Department of  Health and Human Services 
& Food and Drug Administration. Guidance for 
Industry Bioanalytical Method Validation Guid-
ance for Industry Bioanalytical Method Validation. 
(2001). at http://www.fda.gov/downloads/Drugs/
Guidances/ucm070107.pdf
15. Vakulenko SB, Mobashery S. Versatility of  amino-
glycosides and prospects for their future. Clin. Mi-
crobiol. Rev. 16, 430–450 (2003).
16. Hoppentocht M, Akkerman OW, Hagedoorn P et 
al. The Cyclops for pulmonary delivery of  amino-
glycosides; a new member of  the TwincerTM fami-
ly. Eur. J. Pharm. Biopharm. 90, 8–15 (2015). 
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Conclusions
With the adapted method a rapid immunoassay became 
available that enables quantification of  tobramycin con-
centrations as low as 0.03 mg/L and up to 0.6 mg/L. 
The method was validated with representative samples 
and already showed its utility in routine analysis.
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